Effectiveness and safety profile of S‑1‑based chemotherapy compared with capecitabine‑based chemotherapy for advanced gastric and colorectal cancer: A meta‑analysis

Ye,Jia-Xiang; Liu,Ai-Qun; Ge,Lian-Ying; Zhou,Shao-Zhang; Liang,Zhong‑Guo

doi:10.3892/etm.2014.1576

Effectiveness and safety profile of S‑1‑based chemotherapy compared with capecitabine‑based chemotherapy for advanced gastric and colorectal cancer: A meta‑analysis

Authors:
- Jia-Xiang Ye
- Ai-Qun Liu
- Lian-Ying Ge
- Shao-Zhang Zhou
- Zhong‑Guo Liang
View Affiliations

Affiliations: Department of Medical Oncology, The Cancer Institute, Affiliated Tumor Hospital of Guangxi Medical University, Nanning, Guangxi 530021, P.R. China, Department of Radiation Oncology, The Cancer Institute, Affiliated Tumor Hospital of Guangxi Medical University, Nanning, Guangxi 530021, P.R. China
Published online on: February 24, 2014 https://doi.org/10.3892/etm.2014.1576
Pages: 1271-1278

Metrics: Total Views: 0 (Spandidos Publications: | PMC Statistics: )

Metrics: Total PDF Downloads: 0 (Spandidos Publications: | PMC Statistics: )

Cited By (CrossRef): 0 citations Loading Articles...

Abstract

The aim of the present analysis was to compare the efficacy and safety profile of S‑1‑based chemotherapy (SBCT) versus capecitabine‑based chemotherapy (CBCT) for advanced gastric cancer (AGC) and advanced colorectal cancer (ACRC). A meta‑analysis was performed, which included eligible randomized controlled trials (RCTs) that were identified using RevMan 5.1.0 software. A total of 1,064 patients from 11 RCTs, comprising of 527 patients in the SBCT group and 537 patients in the CBCT group, were included in the analysis. For AGC, the meta‑analysis of overall survival (OS) [hazard ratio (HR), 0.98; 95% confidence interval (CI), 0.85‑1.12], time to progression (HR, 0.95; 95% CI, 0.80‑1.12) and overall response rate (ORR) [odds ratio (OR), 1.06; 95% CI, 0.72-1.55] of patients in the SBCT group indicated no statistical significance when compared with those in the CBCT group. Furthermore, for ACRC, a pooled analysis demonstrated no significant difference between the SBCT and CBCT groups (OS: HR, 0.82; 95% CI, 0.61-1.10; progression-free survival: HR, 0.79; 95% CI=0.60‑1.04; ORR: OR, 1.27; 95% CI, 0.91‑1.78). The statistically significant differences identified in the overall meta‑analysis indicated a low incidence of grade 3-4 hand‑foot‑syndrome (OR, 0.15; 95% CI, 0.06‑0.36) in the SBCT group; however no statistically significant difference was observed in the incidence of grade 3-4 anemia, thrombocytopenia, leucopenia, neutropenia, diarrhea, stomatitis or nausea/vomiting. The SBCT treatment exhibited similar efficacy and an approximately equivalent safety profile compared with the CBCT treatment and was an alternative to CBCT for patients with AGC or ACRC; however, further investigation is required to provide confirmation.

View Figures

View References

1	Ferlay J, Shin HR, Bray F, Forman D, Mathers C and Parkin DM: Estimates of worldwide burden of cancer in 2008: GLOBOCAN 2008. Int J Cancer. 127:2893–2917. 2010. View Article : Google Scholar : PubMed/NCBI
2	Meyerhardt JA and Mayer RJ: Systemic therapy for colorectal cancer. N Engl J Med. 352:476–487. 2005. View Article : Google Scholar : PubMed/NCBI
3	Miwa M, Ura M, Nishida M, et al: Design of a novel oral fluoropyrimidine carbamate, capecitabine, which generates 5-fluorouracil selectively in tumours by enzymes concentrated in human liver and cancer tissue. Eur J Cancer. 34:1274–1281. 1998. View Article : Google Scholar
4	Shirasaka T, Shimamato Y, Ohshimo H, et al: Development of a novel form of an oral 5-fluorouracil derivative (S-1) directed to the potentiation of the tumor selective cytotoxicity of 5-fluorouracil by two biochemical modulators. Anticancer Drugs. 7:548–557. 1996. View Article : Google Scholar : PubMed/NCBI
5	Xu RH, Sun GP, Lu HS, et al: A phase III study of S-1 plus cisplatin versus fluorouracil plus cisplatin in patients with advanced gastric or gastroesophageal junction adenocarcinoma. Journal of Clinical Oncology. 31:2013.PubMed/NCBI
6	Muro K, Boku N, Shimada Y, et al: Irinotecan plus S-1 (IRIS) versus fluorouracil and folinic acid plus irinotecan (FOLFIRI) as second-line chemotherapy for metastatic colorectal cancer: a randomised phase 2/3 non-inferiority study (FIRIS study). Lancet Oncol. 11:853–860. 2010. View Article : Google Scholar : PubMed/NCBI
7	Hong YS, Park YS, Lim HY, et al: S-1 plus oxaliplatin versus capecitabine plus oxaliplatin for first-line treatment of patients with metastatic colorectal cancer: a randomised, non-inferiority phase 3 trial. Lancet Oncol. 13:1125–1132. 2012. View Article : Google Scholar : PubMed/NCBI
8	Kim GM, Jeung HC, Rha SY, et al: A randomized phase II trial of S-1-oxaliplatin versus capecitabine-oxaliplatin in advanced gastric cancer. Eur J Cancer. 48:518–526. 2012. View Article : Google Scholar : PubMed/NCBI
9	Lee JL, Kang YK, Kang HJ, et al: A randomised multicentre phase II trial of capecitabine vs S-1 as first-line treatment in elderly patients with metastatic or recurrent unresectable gastric cancer. Br J Cancer. 99:584–590. 2008. View Article : Google Scholar : PubMed/NCBI
10	Zang DY, Chung IJ, Oh HS, Park KU, Lee KH, Han B, Choi DR, Kim HS and Kim JH: Randomized phase II study of oxaliplatin and S-1 (OS) versus oxaliplatin and capecitabine (XELOX) in patients with metastatic or recurrent colorectal cancer. J Clin Oncol. 30:5952012.
11	Ba Z, Wu M, Wang LJ and Zhang HQ: Curative effect analysis of S-1 combined with cisplatin or capecitabine combined with cisplatin in the treatment of advanced gastric cancer. Chinese General Practice. 15:672–676. 2012.
12	Lu HM, Zhou LL, Liu JJ and Liu SH: Clinical study of oxaliplatin plus TS-1 or capecitabine in the treatment of advanced colon cancer. Cancer Research and Clinic. 24:613–615. 2012.
13	Qiu GQ, Xu LZ, Lin ZC and Chen YQ: Clinical observation of S-1 in the treatment of old patients with advanced gastric carcinoma. Chin J Clin Oncol Rehabil. 18:61–63. 2011.
14	Sun DS, Zhang GR, Ma LG and Zou YH: The comparative effect of capecitabine and tegafur/gimeracil/oteracil(S-1) on advanced colorectal cancer. Chin J Prim Med Pharm. 20:826–827. 2013.
15	Xiong HL, Liu XQ, Sun AH, He Y, Li J and Yuan X: Clinical comparison of docetaxel combined with S-1 or Capicitabine in treating advanced gastric carcinoma. Modern Oncology. 21:581–584. 2013.
16	Yan Z, Zhao TX, Xing Y, Chen D and He LL: Curative effect analysis of S-1 combined with cisplatin in the treatment of advanced gastric cancer. Progress in Modern Biomedicine. 12:5324–5326. 2012.
17	Zhang HY and Sun LZ: The clinical study of domestic compound Tegafur capsule first-line Therapy for patients with elderly advanced gastric cancer. Medical Innovation of China. 7:94–96. 2010.
18	Tierney JF, Stewart LA, Ghersi D, Burdett S and Sydes MR: Practical methods for incorporating summary time-to-event data into meta-analysis. Trials. 8:162007. View Article : Google Scholar : PubMed/NCBI
19	Higgins J and Green S: The Chochrane Collaboration: Cochrane Handbook for Systematic Reviews of Interventions. http://www.cochranehandbook.orguri. Accessed August 31, 20132011
20	Therasse P, Arbuck SG, Eisenhauer EA, et al: New guidelines to evaluate the response to treatment in solid tumors. European Organization for Research and Treatment of Cancer, National Cancer Institute of the United States, National Cancer Institute of Canada. J Natl Cancer Inst. 92:205–216. 2000. View Article : Google Scholar : PubMed/NCBI
21	Tsuburaya A, Morita S, Kodera Y, et al: A randomized phase II trial to elucidate the efficacy of capecitabine plus cisplatin (XP) and S-1 plus cisplatin (SP) as a first-line treatment for advanced gastric cancer: XP ascertainment vs. SP randomized PII trial (XParTS II). BMC Cancer. 12:3072012. View Article : Google Scholar : PubMed/NCBI
22	Okines AFC, Norman AR, McCloud P, Kang YK and Cunningham D: Meta-analysis of the REAL-2 and ML17032 trials: evaluating capecitabine-based combination chemotherapy and infused 5-fluorouracil-based combination chemotherapy for the treatment of advanced oesophago-gastric cancer. Ann Oncol. 20:1529–1534. 2009. View Article : Google Scholar
23	Huang J, Cao Y, Wu L, Liao C, He Y and Gao F: S-1-based therapy versus 5-FU-based therapy in advanced gastric cancer: a meta-analysis. Med Oncol. 28:1004–1011. 2011. View Article : Google Scholar : PubMed/NCBI
24	Ma Y, Tang L, Wang HX, Xu YC, Ma Y and Zhang FC: Capecitabine for the treatment for advanced gastric cancer: efficacy, safety and ethnicity. J Clin Pharm Ther. 37:266–275. 2012. View Article : Google Scholar : PubMed/NCBI
25	Ajani JA, Faust J, Ikeda K, et al: Phase I pharmacokinetic study of S-1 plus cisplatin in patients with advanced gastric carcinoma. J Clin Oncol. 23:6957–6965. 2005. View Article : Google Scholar : PubMed/NCBI
26	Kong SY, Lim HS, Nam BH, et al: Association of CYP2A6 polymorphisms with S-1 plus docetaxel therapy outcomes in metastatic gastric cancer. Pharmacogenomics. 10:1147–1155. 2009. View Article : Google Scholar : PubMed/NCBI
27	Fuse N, Fukuda H, Yamada Y, et al: Updated results of randomized phase III study of 5-fluorouracil (5-FU) alone versus combination of irinotecan and cisplatin (CP) versus S-1 alone in advanced gastric cancer (JCOG 9912). J Clin Oncol (ASCO Annual Meeting abstracts). 27:45142009.
28	Ajani JA, Rodriguez W, Bodoky G, et al: Multicenter phase III comparison of cisplatin/S-1 with cisplatin/infusional fluorouracil in advanced gastric or gastroesophageal adenocarcinoma study: the FLAGS trial. J Clin Oncol. 28:1547–1553. 2010. View Article : Google Scholar